Drug intelligence / Profile preview

risankizumab-800CW

Development stage: Phase 2
Lead developer: University Medical Center Groningen
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

Risankizumab-800CW is a fluorescently labeled version of risankizumab, an interleukin-23 antagonist. It was developed for fluorescence molecular imaging to visualize drug targeting and distribution in patients with inflammatory bowel disease (IBD). This imaging agent allows for quantitative fluorescence endoscopy to observe local drug distribution and target cells, potentially improving response prediction in IBD patients.

Targets

IL23A (Interleukin-23 p19 Subunit)

Beyond the preview

Go deeper on risankizumab-800CW.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on risankizumab-800CW.

Explore the full profile